233 related articles for article (PubMed ID: 19480962)
1. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence.
Bonanni P; Boccalini S; Bechini A
Vaccine; 2009 May; 27 Suppl 1():A46-53. PubMed ID: 19480962
[TBL] [Abstract][Full Text] [Related]
2. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
[TBL] [Abstract][Full Text] [Related]
3. Measuring serum antibody to human papillomavirus following infection or vaccination.
Frazer IH
Gynecol Oncol; 2010 Jun; 118(1 Suppl):S8-11. PubMed ID: 20494221
[TBL] [Abstract][Full Text] [Related]
4. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
5. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
6. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
Joura EA; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch X; Dillner J; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Lu S; Vuocolo S; Hesley TM; Haupt RM; Barr E
Vaccine; 2008 Dec; 26(52):6844-51. PubMed ID: 18930097
[TBL] [Abstract][Full Text] [Related]
7. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy of human papillomavirus vaccination.
Ault KA
Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S27-30. PubMed ID: 17938016
[TBL] [Abstract][Full Text] [Related]
9. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
Villa LL
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S17-25. PubMed ID: 18162241
[TBL] [Abstract][Full Text] [Related]
10. Protecting our patients from HPV and HPV-related diseases: the role of vaccines.
Mahoney MC
J Fam Pract; 2006 Nov; Suppl():10-7. PubMed ID: 17366753
[TBL] [Abstract][Full Text] [Related]
11. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
Brown DR; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Tay EH; Garcia P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Sings HL; James M; Hesley TM; Barr E
J Infect Dis; 2009 Apr; 199(7):926-35. PubMed ID: 19236279
[TBL] [Abstract][Full Text] [Related]
12. Development of prophylactic HPV vaccines.
Gissmann L; Müller M
Coll Antropol; 2007 Apr; 31 Suppl 2():113-5. PubMed ID: 17598512
[TBL] [Abstract][Full Text] [Related]
13. Correlating immunity with protection for HPV infection.
Frazer I
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S10-6. PubMed ID: 18162240
[TBL] [Abstract][Full Text] [Related]
14. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
[TBL] [Abstract][Full Text] [Related]
15. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
Dunne EF; Datta SD; E Markowitz L
Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
[TBL] [Abstract][Full Text] [Related]
16. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.
Stanley M; Gissmann L; Nardelli-Haefliger D
Vaccine; 2008 Aug; 26 Suppl 10():K62-7. PubMed ID: 18847558
[TBL] [Abstract][Full Text] [Related]
17. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
Stanley M; Lowy DR; Frazer I
Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
[TBL] [Abstract][Full Text] [Related]
18. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine.
Fraser C; Tomassini JE; Xi L; Golm G; Watson M; Giuliano AR; Barr E; Ault KA
Vaccine; 2007 May; 25(21):4324-33. PubMed ID: 17445955
[TBL] [Abstract][Full Text] [Related]
19. Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines.
Hildesheim A; Markowitz L; Avila MH; Franceschi S
Vaccine; 2006 Aug; 24 Suppl 3():S3/227-32. PubMed ID: 16950011
[TBL] [Abstract][Full Text] [Related]
20. Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States.
Grant LA; Dunne EF; Chesson H; Markowitz LE
Vaccine; 2011 Mar; 29(13):2365-70. PubMed ID: 21277406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
